{"id":"bep-500","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bispecific antibody developed by the Institute of Cancer Research, BEP(500) is designed to bridge immune effector cells with tumor cells or modulate key signaling pathways involved in cancer progression. The exact dual targets and mechanism remain proprietary, but bispecific approaches in oncology typically aim to enhance T-cell activation, redirect immune cells to tumors, or block immunosuppressive pathways.","oneSentence":"BEP(500) is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:07.830Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06081114","phase":"NA","title":"Micronutrient Dose Response Study in Bangladesh","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2023-10-22","conditions":"Micronutrient Status","enrollment":643},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT01726374","phase":"PHASE3","title":"Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2010-02","conditions":"Stage I Testicular Non-Seminomatous Germ Cell Tumor","enrollment":246},{"nctId":"NCT04012177","phase":"NA","title":"Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women - Mumta Pregnant Women Trial","status":"UNKNOWN","sponsor":"Vital Pakistan Trust","startDate":"2019-07-22","conditions":"Undernutrition","enrollment":1884},{"nctId":"NCT03533712","phase":"PHASE4","title":"Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome and Child Growth in Houndé District, Burkina Faso.","status":"COMPLETED","sponsor":"University Ghent","startDate":"2019-10-30","conditions":"Small for Gestational Age at Delivery, Low Birth Weight, Prematurity","enrollment":1788},{"nctId":"NCT04171388","phase":"PHASE4","title":"Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-03-01","conditions":"Low Birthweight, Preterm Birth, Maternal; Malnutrition, Affecting Fetus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEP(500)","genericName":"BEP(500)","companyName":"Institute of Cancer Research, United Kingdom","companyId":"institute-of-cancer-research-united-kingdom","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEP(500) is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance anti-tumor immune responses. Used for Solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}